Q BioMed Inc. (QBIO) Stock Analysis
DELISTED 2026
What happened to Q BioMed Inc. (QBIO) stock?
Q BioMed Inc. (QBIO) no longer trades on public markets. It was delisted in April 2026. The figures below are historical and are not a current quote.
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Q BioMed Inc. (QBIO) trades at $0.0001. Q BioMed Inc. is a biomedical acceleration and development company focused on licensing and acquiring life sciences and healthcare assets. Sector: Healthcare.
Last analyzed: Mar 17, 2026Analyst Coverage for QBIO: QBIO does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates QBIO against Healthcare peers across nine fundamental dimensions and assigns a neutral fundamental signal based on the underlying data.
QBIO: 1/2 scored disciplines lean bullish. Dominant signal: Seth Klarman bullish.
How is this calculated? →Q BioMed Inc. (QBIO) Healthcare & Pipeline Overview
Q BioMed Inc. operates as a biomedical accelerator, acquiring and developing life science assets, including a marketed radiopharmaceutical for bone cancer pain and preclinical candidates targeting glaucoma, autism spectrum disorder, and liver cancer. The company focuses on unmet medical needs within the biotechnology sector.
What Is the Investment Thesis for QBIO?
Q BioMed Inc. presents a high-risk, high-reward investment opportunity within the biotechnology sector. The company's current marketed product, Strontium Chloride SR89, generates revenue, but the company's future growth depends heavily on the successful development and commercialization of its pipeline assets. Key value drivers include the advancement of Man-01 into clinical trials for glaucoma and positive clinical data for QBM-001 in autism spectrum disorder. The company's small size and limited resources pose significant risks, requiring careful monitoring of cash burn and potential dilution. The negative profit margin of -721.7% and gross margin of -3.2% highlight the company's current financial challenges. Investors should closely evaluate the clinical trial timelines and regulatory pathways for Q BioMed's pipeline candidates.
Based on FMP financials and quantitative analysis
QBIO Key Highlights
Q BioMed Inc. operates in the biotechnology sector, focusing on acquiring and developing life science assets.
- The company's portfolio includes Strontium Chloride SR89 and Metastron, radiopharmaceutical therapeutics for metastatic bone cancer pain.
- Q BioMed is developing Man-01 for primary open angle glaucoma, currently in the pre-clinical stage.
- The company is also developing QBM-001 for rare pediatric non-verbal autism spectrum disorder.
- Q BioMed has a partnership with Mannin Research Inc. to develop therapeutics for acute respiratory distress syndrome, glaucoma, and kidney diseases.
Who Are QBIO's Competitors?
QBIO is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ADAPY Adaptimmune Therapeutics plc | $0.03 | +0.00% | $7.16M | 72 |
| RLYB Rallybio Corporation | $16.60 | -2.35% | $88.1M | 81 |
| ICCC ImmuCell Corporation | $10.09 | -0.39% | $91.3M | 77 |
| JNCE Jounce Therapeutics, Inc. | $1.88 | +0.00% | $99.0M | 71 |
| ORMP Oramed Pharmaceuticals Inc. | $4.79 | +0.21% | $196M | 77 |
| CGEN Compugen Ltd. | $2.65 | +8.61% | $251M | 76 |
| NAGE Niagen Bioscience Inc | $3.15 | -0.63% | $251M | 74 |
| ADGI Adagio Therapeutics, Inc. | $4.64 | +0.87% | $506M | 71 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are QBIO's Key Strengths?
Marketed products generating revenue (Strontium Chloride SR89 and Metastron).
- Diverse pipeline of preclinical candidates targeting multiple therapeutic areas.
- Partnership with Mannin Research Inc.
- Experienced management team in life sciences.
What Are QBIO's Weaknesses?
Limited financial resources and high cash burn.
- Dependence on successful development of pipeline assets.
- Small team size and limited infrastructure.
- Negative profit and gross margins.
What Could Drive QBIO Stock Higher?
Initiation of Phase 1 clinical trials for Man-01 in glaucoma (projected by late 2026).
- Initiation of Phase 1 clinical trials for QBM-001 in autism spectrum disorder (projected by early 2027).
- Commercial expansion efforts for Strontium Chloride SR89 and Metastron.
- Evaluation and potential acquisition of new life science assets.
- Advancement of Uttroside-B to IND-enabling studies (projected by mid-2027).
What Are the Key Risks for QBIO?
Financial-distress signal — its Altman Z-Score of -33.23 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Limited financial resources and high cash burn rate.
- Clinical trial failures for pipeline candidates.
- Regulatory setbacks and delays in drug approval.
- Competition from established pharmaceutical companies.
- Product liability claims and intellectual property disputes.
What Are the Growth Opportunities for QBIO?
- Advancement of Man-01 for Glaucoma Treatment: The global glaucoma market is projected to reach $5.9 billion by 2027. Q BioMed's Man-01, a pre-clinical lead candidate, represents a significant growth opportunity if it successfully transitions into clinical trials and demonstrates efficacy. The company's partnership with Mannin Research Inc. could accelerate the development process. Timeline: Initiate Phase 1 trials by late 2026.
- Development of QBM-001 for Autism Spectrum Disorder: The market for autism spectrum disorder treatments is expanding, with increasing awareness and diagnosis rates. QBM-001 targets a specific subset of patients with rare pediatric non-verbal autism, offering a potentially targeted therapy. Positive pre-clinical data and successful Phase 1 trials could drive significant value. Timeline: Initiate Phase 1 trials by early 2027.
- Commercial Expansion of Strontium Chloride SR89 and Metastron: While already marketed, Strontium Chloride SR89 and Metastron offer opportunities for expanded commercialization through strategic partnerships and geographic expansion. Focusing on underserved markets and optimizing distribution channels could increase revenue. The market for bone cancer pain therapeutics is expected to grow steadily. Timeline: Ongoing efforts to expand market reach.
- Licensing and Acquisition of New Assets: Q BioMed's core strategy involves acquiring and licensing promising life science assets. Identifying and securing undervalued or under-resourced assets with strong potential could fuel future growth. A disciplined approach to due diligence and strategic partnerships is crucial. Timeline: Ongoing evaluation of potential acquisition targets.
- Development of Uttroside-B for Liver Cancer: The global liver cancer therapeutics market is expected to grow, driven by increasing incidence rates. Uttroside-B represents a potential new treatment option. Successful pre-clinical development and subsequent clinical trials are essential for realizing this growth opportunity. Timeline: Advance to IND-enabling studies by mid-2027.
What Are QBIO's Competitive Advantages?
- Proprietary drug formulations for Strontium Chloride SR89 and Metastron.
- Intellectual property rights for pipeline candidates like Man-01, QBM-001, and Uttroside-B.
- Established relationships with researchers and clinicians.
- Expertise in acquiring and developing undervalued life science assets.
What Does QBIO Do?
Q BioMed Inc., established in 2013 and based in New York City, is a biomedical acceleration and development company. Originally named ISMO Tech Solutions, Inc., the company rebranded in July 2015 to reflect its focus on acquiring and developing promising life science assets. Q BioMed's core strategy involves licensing and acquiring undervalued or under-resourced life sciences and healthcare companies, providing them with the necessary resources to advance their development programs. The company's portfolio includes Strontium Chloride SR89 and Metastron, radiopharmaceutical therapeutics used for the treatment of metastatic bone cancer pain. Additionally, Q BioMed is actively developing a pipeline of preclinical candidates, including Man-01 for primary open angle glaucoma, QBM-001 for rare pediatric non-verbal autism spectrum disorder, and Uttroside-B for liver cancer. The company also has a partnership with Mannin Research Inc. to develop therapeutics for conditions such as acute respiratory distress syndrome, glaucoma, and kidney diseases. With a small team of 3 employees, Q BioMed operates with a lean structure, focusing on strategic partnerships and efficient resource allocation to advance its development programs.
What Products and Services Does QBIO Offer?
- Acquires and licenses life science and healthcare assets.
- Develops therapeutics for unmet medical needs.
- Markets Strontium Chloride SR89 and Metastron for metastatic bone cancer pain.
- Advances pre-clinical candidates for glaucoma, autism spectrum disorder, and liver cancer.
- Partners with other companies to develop new therapies.
- Provides resources to accelerate the development of acquired assets.
How Does QBIO Make Money?
- Acquire or license promising drug candidates or technologies.
- Develop these assets through preclinical and clinical studies.
- Seek regulatory approval for new therapies.
- Commercialize approved products directly or through partnerships.
What Industry Does QBIO Operate In?
Q BioMed Inc. operates within the competitive biotechnology industry, characterized by high research and development costs, lengthy regulatory approval processes, and significant clinical trial risks. The market for cancer therapeutics, particularly radiopharmaceuticals, is growing, driven by an aging population and increasing cancer incidence. The glaucoma and autism spectrum disorder markets also represent significant opportunities, but competition from established pharmaceutical companies and other biotech firms is intense. Q BioMed's success depends on its ability to efficiently develop and commercialize its pipeline assets in a cost-effective manner.
Who Are QBIO's Key Customers?
- Hospitals and oncology clinics using Strontium Chloride SR89 and Metastron.
- Patients suffering from metastatic bone cancer pain.
- Potential future patients with glaucoma, autism spectrum disorder, and liver cancer.
- Pharmaceutical companies interested in licensing or acquiring Q BioMed's assets.
Financial Health
Q BioMed Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -33.23 places it in the distress zone, a signal of elevated financial risk.
Key Financial Metrics
Return on equity for Q BioMed Inc. stands at 44.1%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -58.4%, showing how much profit it generates from its asset base. A current ratio of 0.01 means current liabilities exceed short-term assets, a liquidity point worth watching.
Company Profile
Q BioMed Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in New York City, US. The company is led by CEO Denis D. Corin. QBIO has traded publicly since 2015.
QBIO Financials
Bull Case vs Bear Case
Bull Case
- AI analysis temporarily unavailable
- Check back shortly for updated insights
- Market sentiment data being refreshed
- Community discussions being analyzed
Bear Case
- AI analysis temporarily unavailable
- Check back shortly for updated insights
- Risk factors being evaluated
- Market concerns being processed
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
QBIO Latest News
No recent news available for QBIO.
Leadership: Denis D. Corin
CEO
Denis D. Corin serves as the CEO of Q BioMed Inc. His background includes experience in the life sciences and healthcare industries, with a focus on business development, strategic planning, and financial management. He has been involved in various aspects of the pharmaceutical and biotechnology sectors, including product development, licensing, and commercialization. His leadership is focused on driving the company's growth through strategic acquisitions and the advancement of its pipeline assets.
Track Record: Under Denis D. Corin's leadership, Q BioMed Inc. has focused on acquiring and developing a portfolio of life science assets, including Strontium Chloride SR89 and Metastron. He has overseen the advancement of preclinical candidates such as Man-01 and QBM-001. Key strategic decisions have included partnerships and licensing agreements aimed at accelerating the development and commercialization of the company's products.
QBIO OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Q BioMed Inc. may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier often have limited trading volume and may be subject to less regulatory oversight compared to companies listed on major exchanges like the NYSE or NASDAQ. Investing in companies on the OTC Other tier carries significant risks due to the potential for limited information and liquidity.
- OTC Tier: OTC Other
- Limited financial disclosure and potential for information asymmetry.
- Low trading volume and liquidity, increasing price volatility.
- Higher risk of fraud or manipulation compared to listed exchanges.
- Potential for delisting or trading suspension.
- Limited regulatory oversight and investor protection.
- Verify the company's financial statements and SEC filings (if any).
- Research the background and experience of the management team.
- Assess the company's business model and competitive landscape.
- Evaluate the company's intellectual property and regulatory approvals.
- Monitor trading volume and price volatility.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor before investing.
- FDA-approved products (Strontium Chloride SR89 and Metastron) indicate some level of regulatory compliance.
- Partnership with Mannin Research Inc. suggests external validation of the company's technology.
- Focus on developing therapies for unmet medical needs aligns with broader healthcare goals.
- Company has been in operation since 2013.
- Publicly traded status, even on the OTC market, requires some level of transparency.
What Investors Ask About Q BioMed Inc. (QBIO) — Healthcare
What happened to Q BioMed Inc. (QBIO) stock?
Q BioMed Inc. (QBIO) no longer trades on public markets. It was delisted in April 2026. The figures below are historical and are not a current quote.
Can I still buy QBIO shares?
No. QBIO stopped trading on public markets in April 2026, so the shares are not available through a broker. Anything you see quoted for QBIO elsewhere is historical data, not a live market.
Are the figures on this page current?
No. Every number here is the last value recorded before QBIO stopped trading. Nothing on this page updates, and none of it is a current quote.
Why does this page still exist?
Because people still search for what happened to Q BioMed Inc.. An archived profile that states the delisting plainly is more useful than a dead link — provided it is labelled as history, which is what this page does.
What does Q BioMed Inc. do?
Q BioMed Inc. is a biomedical acceleration and development company that focuses on acquiring, licensing, and developing promising life science assets. The company's current portfolio includes Strontium Chloride SR89 and Metastron, radiopharmaceutical therapeutics for metastatic bone cancer pain. Additionally, Q BioMed is developing a pipeline of preclinical candidates targeting conditions such as glaucoma, autism spectrum disorder, and liver cancer.
What do analysts say about QBIO stock?
As of 2026-03-17, formal analyst ratings and price targets for QBIO are Unknown, likely due to its OTC listing and small market capitalization. Investors should conduct their own due diligence and consider the company's financial condition, pipeline progress, and potential risks before making any investment decisions.
What are the main risks for QBIO?
Q BioMed Inc. faces several significant risks, including limited financial resources, high cash burn, and dependence on the successful development of its pipeline assets. Clinical trial failures or regulatory setbacks could severely impact the company's prospects. Competition from established pharmaceutical companies with greater resources poses a constant threat.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited information available for OTC-listed companies.
- Financial data may not be fully up-to-date.
- AI analysis pending for QBIO.